Synlogic to present data on phenylketonuria and homocystinuria programs at the society for inherited metabolic disorders 43rd annual meeting

Cambridge, mass., april 01, 2022 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that data from its phenylketonuria (pku) and homocystinuria (hcu) programs will be highlighted in two poster presentations at the society for inherited metabolic disorders (simd) 43rd annual meeting being held april 10-13, 2022 in orlando, florida.
SYBX Ratings Summary
SYBX Quant Ranking